Rituximab immune monitoring (No longer perfomed by CTL)

Description: 
Immunofluorescence testing for CD3 and CD19 markers determine the absolute count of cells expressing these antigens
Clinical details: 
Patients receiving rituximab therapy are monitored to determine the concentration of CD19 cells. This determines the efficacy of the drug.
Related condition or disease: 
ABO blood group incompatible transplantation
Nephrotic Syndrome
Reference range: 

none

Synonyms or keywords: 
CD19 CD20 B cell rituximab
Units: 
cells/µl
Department: 
Clinical Transplantation Department
Location: 
Guy's Hospital
Sample type and Volume required: 
N/A
Call in advance: 
Call Special Haematology 020 7188 3421
Criteria for acceptance / rejections of sample
Contacts:
Clinical Transplantation Department at Guy's Hospital
Laboratory Enquiry: 020 7188 1540
Clinical Transplantation Department
Guy's Hospital
Borough Wing - 3rd Floor
Great Maze Pond
London SE1 9RT
For clinical advice or interpretation of results, please contact the laboratory in the first instance.
Laboratory: 
Clinical Transplantation Laboratory at Guy's Hospital

Print as a PDF

Last updated: 12/05/2016